Editorial: Rifaximin and the Gut–Liver–Brain Axis—Progress and Prudence
Alimentary Pharmacology & Therapeutics · 2026-09 · 64 (5) · 681-682
DOI: 10.1111/apt.70809 ↗At a glance
Editorial in Alimentary Pharmacology & Therapeutics, published online on 2026-06-21. Written by Kevin V Houston and 1 co-authors. Institution: Virginia Commonwealth University and Richmond VA Medical Center, Richmond, Virginia, USA. Cited 2 times so far (Crossref); 10 references. The full text is freely available in PubMed Central. Funded by: U.S. Department of Veterans Affairs, CSRD VA, NIAAA NIH HHS.
Abstract (original language)
Intet abstract tilgængeligt.
Authors and institutions
- Virginia Commonwealth University and Richmond VA Medical Center, Richmond, Virginia, USA.
Funding
- U.S. Department of Veterans Affairs
- CSRD VA
- NIAAA NIH HHS
- National Institute on Alcohol Abuse and Alcoholism
Cite
APA
Houston, K. V., & Bajaj, J. S. (2026). Editorial: Rifaximin and the Gut–Liver–Brain Axis—Progress and Prudence. Alimentary Pharmacology & Therapeutics, 64(5), 681-682. https://doi.org/10.1111/apt.70809
Vancouver
Houston KV, Bajaj JS. Editorial: Rifaximin and the Gut–Liver–Brain Axis—Progress and Prudence. Alimentary Pharmacology & Therapeutics. 2026;64(5):681-682. doi:10.1111/apt.70809
BibTeX
@article{Houston2026,
author = {Houston, Kevin V and Bajaj, Jasmohan S},
title = {Editorial: Rifaximin and the Gut–Liver–Brain Axis—Progress and Prudence},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2026},
volume = {64},
number = {5},
pages = {681--682},
doi = {10.1111/apt.70809}
}
EUVIMED